• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Time to escalate quality assurance in small-cell lung cancer radiotherapy trials - Authors' reply.

作者信息

Yu Jiayi, Zhao Jun, Shi Anhui

机构信息

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.

出版信息

Lancet Respir Med. 2024 Dec;12(12):e76. doi: 10.1016/S2213-2600(24)00335-7.

DOI:10.1016/S2213-2600(24)00335-7
PMID:39638534
Abstract
摘要

相似文献

1
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials - Authors' reply.是时候加强小细胞肺癌放疗试验中的质量保证了——作者回复
Lancet Respir Med. 2024 Dec;12(12):e76. doi: 10.1016/S2213-2600(24)00335-7.
2
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials.
Lancet Respir Med. 2024 Dec;12(12):e75. doi: 10.1016/S2213-2600(24)00338-2.
3
Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.针对非小细胞肺癌引起胸部症状患者的姑息性放疗方案。
Cochrane Database Syst Rev. 2015 Jan 14;1(1):CD002143. doi: 10.1002/14651858.CD002143.pub4.
4
Is it time to convert the frequency of radiotherapy in small-cell lung cancer? - Authors' reply.是时候改变小细胞肺癌的放疗频率了吗？——作者回复
Lancet Oncol. 2017 Oct;18(10):e556. doi: 10.1016/S1470-2045(17)30611-3.
5
Surgery for limited-stage small-cell lung cancer.局限期小细胞肺癌的手术治疗
Cochrane Database Syst Rev. 2017 Apr 21;4(4):CD011917. doi: 10.1002/14651858.CD011917.pub2.
6
Radiotherapy for extensive stage small-cell lung cancer - Authors' reply.广泛期小细胞肺癌的放射治疗——作者回复
Lancet. 2015 Apr 4;385(9975):1292-3. doi: 10.1016/S0140-6736(15)60679-1.
7
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法（不包括检查点抑制剂）。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
8
Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.非小细胞肺癌的全脑放疗——作者回复
Lancet. 2017 Apr 8;389(10077):1395-1396. doi: 10.1016/S0140-6736(17)30892-9.
9
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.手术或放疗根治性治疗的 I 期至 III 期非小细胞肺癌的免疫治疗（不包括检查点抑制剂）。
Cochrane Database Syst Rev. 2021 Dec 6;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub3.
10
[F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer - Authors' reply.
Lancet Oncol. 2024 Nov;25(11):e541. doi: 10.1016/S1470-2045(24)00578-3.

引用本文的文献

1
Evolving roles of MET as a therapeutic target in NSCLC and beyond.MET作为非小细胞肺癌及其他疾病治疗靶点的角色演变。
Nat Rev Clin Oncol. 2025 Jul 18. doi: 10.1038/s41571-025-01051-9.
2
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.表皮生长因子受体（EGFR）突变型非小细胞肺癌不断变化的治疗格局。
Nat Rev Clin Oncol. 2025 Feb;22(2):95-116. doi: 10.1038/s41571-024-00971-2. Epub 2024 Nov 29.